Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
AVAX Technologies Announces Initiation of Clinical Study with Autologous Ovarian Cancer Vaccine (OVax(R))
April 23rd, 2008
AVAX Technologies, Inc. (OTC Market:AVXT.OB) announces it has received FDA approval to begin enrollment into a Phase I-II clinical trial of OVax for patients with advanced, chemotherapy-refractive ovarian cancer. The study will be performed in collaboration with Cancer Treatment Centers of America, Inc (CTCA). It will be centered in the CTCA hospital in Zion, Illinois, although patients also will be referred from other CTCA hospitals in Tulsa and Philadelphia, and its out-patient clinic in Seattle. Up to 42 eligible patients with stage III or IV ovarian carcinoma will be enrolled. These patients' cancers will have progressed despite initial surgery and chemotherapy and...
Source: Vaccine Weekly (2008-04-23)
|
